<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02764151</url>
  </required_header>
  <id_info>
    <org_study_id>C0591001</org_study_id>
    <nct_id>NCT02764151</nct_id>
  </id_info>
  <brief_title>First in Patient Study for PF-06840003 in Malignant Gliomas</brief_title>
  <official_title>A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06840003 In Patients With Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of increasing doses of PF-06840003 in
      patients with malignant gliomas.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 9, 2016</start_date>
  <completion_date type="Anticipated">October 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose Limiting Toxicities (DLTs) [Part 1]</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>First cycle DLTs in order to determine the maximum tolerated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with disease control [Part 2]</measure>
    <time_frame>Baseline, Week 9 and Week 25</time_frame>
    <description>Disease control rate at 9 and 25 weeks by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with laboratory abnormalities</measure>
    <time_frame>Baseline until disease progression or unacceptable toxicity, or up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with vital sign abnormalities</measure>
    <time_frame>Baseline until disease progression or unacceptable toxicity, or up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective response</measure>
    <time_frame>Baseline and every 8 weeks until disease progression, unacceptable toxicity, or up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Cycle 1 Day 1 0, 1, 2, 4, 6, 8, 24 hrs post, Day 4, Day 8, Day 15 0, 1, 2, 4, 6, 8, 24 hr post, Day 1 and Day 15 of subsequent cycles, and up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Cycle 1 Day 1 0, 1, 2, 4, 6, 8, 24 hrs post, Day 4, Day 8, Day 15 0, 1, 2, 4, 6, 8, 24 hr post, Day 1 and Day 15 of subsequent cycles, and up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from time zero to end of dosing interval (AUCtau)</measure>
    <time_frame>Cycle 1 Day 1 0, 1, 2, 4, 6, 8, 24 hrs post, Day 4, Day 8, Day 15 0, 1, 2, 4, 6, 8, 24 hr post, Day 1 and Day 15 of subsequent cycles, and up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with disease control based on the iRANO criteria</measure>
    <time_frame>Baseline, Week 9 and Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma kynurenine, tryptophan and kyn/trp ratio</measure>
    <time_frame>Cycle 1 Day 1 0, 1, 2, 4, 6, 8, 24 hrs post, Day 4, Day 8, Day 15 0, 1, 2, 4, 6, 8, 24 hr post and at the time of treatment discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state trough level ratio</measure>
    <time_frame>Baseline and Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Oligodendroglioma</condition>
  <condition>Astrocytoma</condition>
  <condition>Malignant Glioma</condition>
  <arm_group>
    <arm_group_label>PF-06840003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily Oral PF-06840003</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06840003</intervention_name>
    <description>Daily Oral PF-06840003</description>
    <arm_group_label>PF-06840003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of WHO Grade IV glioblastoma or WHO Grade III anaplastic gliomas

          -  For patients with Grade IV GBM, recurrent disease at the time of the first or second
             recurrence or progression. For patients with Grade III anaplastic gliomas, recurrent
             disease at the time of at least a first recurrence but no more than a fourth
             recurrence or progression

          -  Karnofsky performance score greater than or equal to 70%

          -  Adequate bone marrow, kidney and liver function

        Exclusion Criteria:

          -  History of CNS bleeding within 6 months of registration

          -  Previous anti-angiogenics or anti-vascular endothelial growth factor within 12 months
             of registration

          -  Requires treatment with high dose systemic corticosteroids defined as &gt;2 mg/day

          -  Radiation therapy within 12 weeks of registration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center, Drug Information Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-6894</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-6894</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Clinical &amp; Translational Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Oncology Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Comprehensive Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CUMC Research Pharmacy</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Doctors Tarrytown</name>
      <address>
        <city>Tarrytown</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center, Duke Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C0591001&amp;StudyName=A+Phase+1+Dose+Escalation+Study+Evaluating+The+Safety+And+Tolerability+Of+Pf-06840003+In+Patients+With+Malignant+Gliomas</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GBM</keyword>
  <keyword>malignant glioma</keyword>
  <keyword>glioma</keyword>
  <keyword>anaplastic glioma</keyword>
  <keyword>astrocytoma</keyword>
  <keyword>IDO</keyword>
  <keyword>IDO1</keyword>
  <keyword>PF-06840003</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

